Company news
AB Science SA news in 2026
AB Science SA's news releases, calls and decks from 2026, newest first.
AB Science will hold a web conference on Wednesday, October 14, 2026, from 6: 00 p.m. to 7: 30 p.m.
October 11, 2026
Revenues for the first half of 2026 and update on AB Science’s activities
October 9, 2026
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
October 9, 2026
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
September 28, 2026
AB Science fait le point sur son plan de developpement et son calendrier financier à la suite d'une inspection promoteur des bonnes pratiques cliniques
September 28, 2026
AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
August 16, 2026
AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million
August 10, 2026
AB Science annonce aujourd’hui le succès d’augmentations de capital d’un montant brut total de 14,2 millions d’euros
August 9, 2026
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
July 10, 2026
AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
July 9, 2026
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
June 29, 2026
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
June 17, 2026
AB Science: Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share
June 2, 2026
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
May 25, 2026
AB Science reports its revenues for the year 2025 and provides an update on its activities
May 13, 2026
AB Science announces the successful completion of a EUR 3.2 million private placement
April 29, 2026
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
April 27, 2026
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
April 20, 2026
AB Science provides an update on its clinical development program.
April 16, 2026
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
February 24, 2026
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
February 9, 2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer
January 29, 2026
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
January 21, 2026
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
January 7, 2026
Decks in 2026
- Investor Presentation (January 2026)
Investor deck · 33 slides · January 2026